Monitoring of patients receiving eculizumab
Monitoring of patients receiving Eculizumab treatment is required and the National aHUS Service requires this information to report to NHS England as described in the shared care protocol.
- Monitoring in the early stages of treatment will be based on clinical need and local protocols
Testing for evidence of complement blockade by CH100, AH100 (or CH50/AH500) and soluble C5b-9 is recommended during follow-up whilst the patient is receiving Eculizumab.
Samples should be sent for monitoring once patients are stable on eculizumab: every 3 months in the first year of treatment and then annually thereafter.
Additional samples may be required and will be discussed with the referring consultant on a case-by-case basis.
Samples should be sent to the combined aHUS lab diagnostic service
In stable patients the following tests are recommended on a monthly basis:
Full blood count
- Urine Protein/Creatinine ratio
Monitoring is required for titres following meningococcal vaccination as described in the meningococcal guidance.